News

B244, which is presently being readied for international Phase III clinical trials, is a therapeutic treatment aimed at inflammatory indications such as atopic dermatitis, addressing both appearance and

The facility, which is part of the company’s strategic growth plan, aims to enhance pharmaceutical development and manufacturing offerings in Asia. This will aid in meeting the increasing

This therapy is designed for the treatment of multiple sclerosis (MS), a chronic neurodegenerative autoimmune disease. CAR T-cell therapy involves modifying a patient’s T cells to target and

This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access

This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.

Received through the foundation’s Inflammatory Bowel Disease (IBD) Ventures programme, this payment is part of a priorly disclosed grant under research programme agreement with Giiant Pharma to support

In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such

Designed based on the Ligand and Enhancer Assisted Delivery (LEAD) platform of SanegeneBio, SGB-3908 is currently in the investigational new drug application (IND)-enabling stage of development. Both Innovent

A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two